Trials / Unknown
UnknownNCT04965220
HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors
A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and initial efficacy of HLX208 (BRAF V600E inhibitor) in combination with trametinib in patients with advanced solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX 208 | take orally |
Timeline
- Start date
- 2022-01-05
- Primary completion
- 2024-06-30
- Completion
- 2025-06-30
- First posted
- 2021-07-16
- Last updated
- 2023-08-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04965220. Inclusion in this directory is not an endorsement.